Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting
“Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” SOLANA BEACH, Calif. , and CHICAGO , July 25, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused
View HTML
Toggle Summary Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment
Study between nasal and oral metoclopramide selected by Digestive Disease Week (DDW) 2023 faculty for plenary presentation SOLANA BEACH, Calif. , June 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for
View HTML
Toggle Summary Evoke Pharma Reports First Quarter 2023 Financial Results
Net product sales increased by 94% from Q1 2022 New cumulative prescribers up by 17% from Q4 2022 Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif. , May 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily
View HTML
Toggle Summary Real-World Data Presented by Evoke Pharma and EVERSANA at Digestive Disease Week 2023 Shows Gimoti® Meaningfully Reduces Utilization of Healthcare Resources
Patients treated with Gimoti® (metoclopramide) nasal spray showed statistically significant fewer emergency department visits, inpatient hospitalizations, and physician office visits than patients who were treated with oral metoclopramide SOLANA BEACH, Calif.
View HTML
Toggle Summary Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023
Compelling data elevated to distinguished DDW oral plenary session GIMOTI to be showcased in additional activities at conference SOLANA BEACH, Calif. , May 04, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK),  a specialty pharmaceutical company focused primarily on treatments for
View HTML
Toggle Summary New GIMOTI Patent Listed in FDA Orange Book
Broad Formulation Patent Expands Protection for Gimoti SOLANA BEACH, Calif. , May 01, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK),  a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ®  (metoclopramide)
View HTML
Toggle Summary United States Patent and Trademark Office (USPTO) Grants Evoke Pharma a Formulation Patent Covering GIMOTI
The Company Will Submit for FDA Orange-Book Listing in the Near Term SOLANA BEACH, Calif. , April 20, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI®
View HTML
Toggle Summary Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related Patent
SOLANA BEACH, Calif. , April 06, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced the United States Patent and
View HTML
Toggle Summary Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023
Data Demonstrated Reduced Use of Healthcare Resources among Patients Treated with GIMOTI SOLANA BEACH, Calif. , March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma , Inc. (NASDAQ: EVOK),   a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an
View HTML
Toggle Summary Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results
Fiscal year 2022 net   product   sales   from   prescriptions   increased   by 179% to   $2.5 million   versus   2021 Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif. , March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical
View HTML